SCHEMBL12280321

SCHEMBL12280321

CC(C)(C)OC(=O)N1CCC[C@H](Nc2cc(Cl)ncc2C(=O)O)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 5/20 0.47
BRD4 O60885 1/20 0.42
ANO1 Q5XXA6 1/20 0.42
CNR1 P21554 2/20 0.42
CNR2 P34972 1/20 0.42
PARP1 P09874 1/20 0.42
BTK Q06187 1/20 0.42
PIM1 P11309 2/20 0.41
PIM2 Q9P1W9 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
GFER P55789 1/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HPGDS O60760 1/20 0.41
PIK3CD O00329 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24950095 1.00 USP30 (0.47) USP30BRD4ANO1CNR1CNR2
SCHEMBL30194622 0.97 USP30 (0.44) USP30BRD4ANO1CNR1CNR2
SCHEMBL30194552 0.97 USP30 (0.44) USP30BRD4ANO1CNR1CNR2
SCHEMBL18341494 0.94 USP30 (0.49) USP30BRD4CNR1BTKMEN1
SCHEMBL29894214 0.94 USP30 (0.49) USP30BRD4CNR1BTKMEN1
SCHEMBL23301762 0.94 USP30 (0.49) USP30BRD4CNR1BTKMEN1
SCHEMBL28636898 0.94 USP30 (0.49) USP30BRD4CNR1BTKMEN1
SCHEMBL30194554 0.92 CNR1 (0.47) USP30BRD4CNR1MEN1USP2
SCHEMBL30194646 0.92 CNR1 (0.47) USP30BRD4CNR1MEN1USP2
SCHEMBL24949939 0.91 USP30 (0.46) USP30BRD4ANO1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509457-B2 Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-12-30 US disclosed
US-20230014742-A1 BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-01-19 US disclosed
US-20230014742-A1 BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-01-19 US disclosed
US-20110230467-A1 4,6-DIAMINONICOTINAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-09-22 US disclosed
US-20110230467-A1 4,6-DIAMINONICOTINAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230467-A1 4,6-DIAMINONICOTINAMIDE COMPOUND JAK3, JAK2, JAK1 USP30 2926/4885BRD4 417/4885ANO1 1934/4885
US-20230014742-A1 BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 SIK2, SIK1, SIK3 USP30 4590/4885BRD4 257/4885ANO1 2833/4885
US-12509457-B2 Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 SIK2, SIK1, SIK3 USP30 4703/4885BRD4 665/4885ANO1 3596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.